| Description: |
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multireceptor tyrosine kinases (RTKs), including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM and 7.2 nM in cell analysis, respectively. XL092 has antitumor activity. |
| Stability and Solubility Advice: |
Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide.
We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials and used within 1 month. Avoid repeated freeze and thaw cycles. Storage conditions for some special products should refer to their storage details. |
